About the Company
biovie inc. (otc pink: bivi) is developing novel drug therapies for life-threatening complications of chronic liver disease. our initial target is ascites, which can occur in patients with advanced cirrhosis due to hepatitis, nash (non-alcoholic steatohepatitis), or alcoholism. ascites affects about 100,000 americans and carries an estimated 40% mortality rate within two years of being diagnosed. the company’s new drug candidate biv201 is about to enter a phase 2 clinical trial in the us. it’s based on a drug (terlipressin) not yet available in the us, but approved in about 40 countries for treating related complications of liver cirrhosis. the fda has never approved a drug to treat ascites and there is a significant unmet medical need for our novel therapy, which has orphan drug status. biovie has attracted funding from strategic investors including aspire capital, cuong do, the global strategy lead for samsung, and hari kumar, founder of adheron therapeutics which he sold to roche fo
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BIVI News
Shareholders that lost money on BioVie Inc.(BIVI) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / March 18, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow ...
Lost Money on BioVie Inc.(BIVI)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / March 16, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a ...
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVie
If you suffered losses exceeding $25,000 investing in BioVie stock or options between August 5, 2021 and November 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner ...
Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now
BioVie Inc. (BIVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among ...
Why BioVie (BIVI) Shares Are Down 40%
BioVie Inc (NASDAQ:BIVI) shares are trading lower by 42% to $1.09 during Monday’s session. The company announced the pricing ...
Why BioVie Shares Are Trading Lower By Around 42%; Here Are 20 Stocks Moving Premarket
Shares of BioVie Inc. (NASDAQ: BIVI) fell sharply in today’s pre-market trading after the company reported pricing of public offering. BioVie shares dipped 41.8% to $1.10 in pre-market trading Here ...
BioVie cuts 'most de-risked program,' will seek partners for phase 3-ready ascites program
Even after raising $21 million in equity last week, BioVie is still axing the biotech’s “most de-risked program,” a phase ...
BioVie to kick off Phase 2b trial for lead asset in Parkinson’s disease in late-summer
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return ...
BioVie Inc. Announces Pricing of Public Offering
CARSON CITY, Nev., March 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic ...
BioVie jumps as Alzheimer’s drug selected for presentations
BioVie's (BIVI) stock surged after the biotech announced upcoming presentations on its Alzheimer's drug NE3107. Read more ...
Loading the latest forecasts...